Cargando…
Validation of CP‐GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study
BACKGROUND: Approximately 85% of melanoma patients who undergo a sentinel lymph node biopsy (SLNB) are node‐negative. Melanoma incidence is highest in patients ≥65 years, but their SLNB positivity rate is lower than in younger patients. CP‐GEP, a model combining clinicopathologic and gene expression...
Autores principales: | Yousaf, Ahmed, Tjien‐Fooh, Félicia J., Rentroia‐Pacheco, Barbara, Quattrocchi, Enrica, Kobic, Ajdin, Tempel, Dennie, Kolodney, Michael, Meves, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251603/ https://www.ncbi.nlm.nih.gov/pubmed/33914348 http://dx.doi.org/10.1111/ijd.15594 |
Ejemplares similares
-
Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?
por: Rentroia‐Pacheco, Barbara, et al.
Publicado: (2021) -
Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study
por: Hieken, Tina J., et al.
Publicado: (2022) -
Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis
por: Thao, Viengneesee, et al.
Publicado: (2022) -
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
por: Bellomo, Domenico, et al.
Publicado: (2020) -
Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2022)